FDA Reclassification of Melanoma Detection Devices: Optical Diagnostic and Electrical Impedance Devices Downgraded to Class II with Special Controls

The FDA has issued a final order reclassifying two categories of skin cancer diagnostic devices — optical diagnostic devices for melanoma detection (product code OYD) and electrical impedance spectrometers (product code ONV) — from postamendments Class III (highest regulatory tier, requiring Premarket Approval) down to Class II (moderate risk, requiring only Premarket Notification/510(k)). This change reduces the regulatory burden for manufacturers of these devices while maintaining patient safety through newly established special controls. As part of this reclassification, both device types are being renamed and consolidated under a single new classification: 'software-aided adjunctive diagnostic devices for use on skin lesions by physicians trained in the diagnosis and management of skin cancer.' This name reflects the software-driven nature of modern versions of these tools and their role as adjuncts — not replacements — for physician judgment. FDA is simultaneously codifying special controls specific to these devices, which manufacturers must comply with to demonstrate a reasonable assurance of safety and effectiveness. These special controls likely include performance testing standards, labeling requirements (including limitations on intended use), and clinical performance benchmarks. The 'adjunctive' framing is critical: these devices are explicitly intended only to assist trained specialists, not to be used as standalone diagnostic tools. The practical effect for manufacturers is significant: transitioning from Class III to Class II eliminates the need for a full Premarket Approval (PMA) application — a lengthy, expensive process — and instead permits clearance via the faster 510(k) pathway, potentially accelerating market access for new melanoma detection technologies.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.